Abstract
Alzheimer's disease (AD) is the most common cause of dementia worldwide. Although, many putative biomarkers are reported for AD, only a few have been validated in the clinical setting. Ubiquitin levels increase in cerebrospinal fluid (CSF) of patients with AD, but its diagnostic value is not clear. In this present study we evaluate the performance of ubiquitin as a diagnostic marker and deduce a statistical association with disease pathology in AD. Ubiquitin levels were estimated in subjects with AD, other forms of dementias, neurological disorders and healthy age matched population. The levels of ubiquitin were significantly higher in subjects with AD when compared with other groups (p<0.0001). A significant positive correlation was observed between ubiquitin, tau and apolipoprotein Eε4 genotype; with Aβ42 the correlation was negative. By comparing the effect size of the association between ubiquitin and a diagnosis of AD, we find that high ubiquitin levels are specific for AD. We obtained an odds ratio of 5.6 (95% CI 5.0-7.7) for ubiquitin, towards a diagnosis of AD based on clinical criteria, CSF biomarker signature (Aβ42+tau) and apolipoprotein Eε4 genotype. Hence, all our findings taken together provide a strong statistical association linking ubiquitin to the pathology in AD. We also find that, the performance of ubiquitin as a diagnostic marker is comparable to that of CSF Aβ42 or tau or apolipoprotein Eε4 genotype considered individually.
Keywords: Alzheimer's disease, amyloid beta, apolipoprotein Eε4. biomarkers, cerebrospinal fluid, ubiquitin.
Current Alzheimer Research
Title:CSF Ubiquitin As a Specific Biomarker in Alzheimer's Disease
Volume: 11 Issue: 4
Author(s): Ramesh J. Kandimalla, R. Anand, R. Veeramanikandan, Willayat Yousuf Wani, Sudesh Prabhakar, Vinod K. Grover, Neerja Bharadwaj, Kajal Jain and Kiran Dip Gill
Affiliation:
Keywords: Alzheimer's disease, amyloid beta, apolipoprotein Eε4. biomarkers, cerebrospinal fluid, ubiquitin.
Abstract: Alzheimer's disease (AD) is the most common cause of dementia worldwide. Although, many putative biomarkers are reported for AD, only a few have been validated in the clinical setting. Ubiquitin levels increase in cerebrospinal fluid (CSF) of patients with AD, but its diagnostic value is not clear. In this present study we evaluate the performance of ubiquitin as a diagnostic marker and deduce a statistical association with disease pathology in AD. Ubiquitin levels were estimated in subjects with AD, other forms of dementias, neurological disorders and healthy age matched population. The levels of ubiquitin were significantly higher in subjects with AD when compared with other groups (p<0.0001). A significant positive correlation was observed between ubiquitin, tau and apolipoprotein Eε4 genotype; with Aβ42 the correlation was negative. By comparing the effect size of the association between ubiquitin and a diagnosis of AD, we find that high ubiquitin levels are specific for AD. We obtained an odds ratio of 5.6 (95% CI 5.0-7.7) for ubiquitin, towards a diagnosis of AD based on clinical criteria, CSF biomarker signature (Aβ42+tau) and apolipoprotein Eε4 genotype. Hence, all our findings taken together provide a strong statistical association linking ubiquitin to the pathology in AD. We also find that, the performance of ubiquitin as a diagnostic marker is comparable to that of CSF Aβ42 or tau or apolipoprotein Eε4 genotype considered individually.
Export Options
About this article
Cite this article as:
Kandimalla J. Ramesh, Anand R., Veeramanikandan R., Wani Yousuf Willayat, Prabhakar Sudesh, Grover K. Vinod, Bharadwaj Neerja, Jain Kajal and Gill Dip Kiran, CSF Ubiquitin As a Specific Biomarker in Alzheimer's Disease, Current Alzheimer Research 2014; 11 (4) . https://dx.doi.org/10.2174/1567205011666140331161027
DOI https://dx.doi.org/10.2174/1567205011666140331161027 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer’s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Weight Loss and the Risk of Dementia: A Meta-analysis of Cohort Studies
Current Alzheimer Research A Practical Approach to Diagnosis and Treatment of Symptomatic Thromboembolic Events in Children with Acute Lymphoblastic Leukemia: Recommendations of the “Coagulation Defects” AIEOP Working Group
Recent Patents on Cardiovascular Drug Discovery Possible Involvement of Muscarinic Receptors in Psychiatric Disorders: A Focus on Schizophrenia and Mood Disorders
Current Molecular Medicine Beneficial Effects of Lysosome-Modulating and Other Pharmacological and Nanocarrier Agents on Amyloid-beta-treated Cells
Current Pharmaceutical Biotechnology Meet Our Associate Editor
Current Molecular Medicine Circulating Exosomes and Their Role in Stroke
Current Drug Targets Impaired Translation of Spatial Representation in Young Onset Alzheimer’s Disease Patients
Current Alzheimer Research Editorial (Thematic Issue: Effective and Promising Treatments for Neurological Disorders and Cancer)
Current Pharmaceutical Design Gastrointestinal Hemorrhage is Associated with Mortality after Acute Ischemic Stroke
Current Neurovascular Research The Role of Metabolizing Enzymes and Transporters in Antiretroviral Therapy
Current Topics in Medicinal Chemistry Cardiac Workup of Ischemic Stroke
Current Cardiology Reviews Immune-Inflammatory Responses and Oxidative Stress in Alzheimers Disease: Therapeutic Implications
Current Pharmaceutical Design Substance Abuse and Movement Disorders: Complex Interactions and Comorbidities
Current Drug Abuse Reviews Neuroimaging Features of Acquired Metabolic and Toxic Encephalopathies
Current Medical Imaging Selegiline (l-Deprenyl) as a Unique Neuroprotective Agent for Chronic Neurodegenerative Disorders- A Lesson from MAO Inhibition
Current Medicinal Chemistry - Central Nervous System Agents Mood, Memory and Movement: An Age-Related Neurodegenerative Complex?
Current Aging Science Integration of LC-LTQ-Orbitrap-MS and Network Pharmacology to Analyze the Active Components of Sijunzi Decoction and their Mechanism of Action Against Cytotoxicity-associated Premature Ovarian Insufficiency
Combinatorial Chemistry & High Throughput Screening Endogenous Retroelements in Cellular Senescence and Related Pathogenic Processes: Promising Drug Targets in Age-Related Diseases
Current Drug Targets Targeted Drug Delivery to Central Nervous System (CNS) for the Treatment of Neurodegenerative Disorders: Trends and Advances
Central Nervous System Agents in Medicinal Chemistry Glutamate and Mitochondria: Two Prominent Players in the Oxidative Stress-Induced Neurodegeneration
Current Alzheimer Research